Nu-Med Plus (NUMD) EPS (Diluted) Growth (1y) (2016 - 2025)
Nu-Med Plus (NUMD) EPS (Diluted) Growth (1y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.10 Bn | 176.81 Bn | 6.27 Bn | -18.71% |
| 2 | Stryker | 128.79 Bn | 125.91 Bn | 3.81 Bn | 13.88% |
| 3 | Medtronic | 108.97 Bn | 99.75 Bn | 6.41 Bn | 18.72% |
| 4 | Boston Scientific | 68.57 Bn | 67.12 Bn | 3.61 Bn | 98.71% |
| 5 | Edwards Lifesciences | 47.64 Bn | 43.97 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 28.40 Bn | 26.11 Bn | 1.98 Bn | -29.80% |
| 7 | Dexcom | 28.32 Bn | 27.20 Bn | 750.30 Mn | 95.96% |
| 8 | Smith & Nephew | 26.94 Bn | 26.36 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | 114.19% |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | -19.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -19.55% |
| Sep 30, 2025 | 37.62% |
| Jun 30, 2025 | 34.30% |
| Mar 31, 2025 | 8.67% |
| Dec 31, 2024 | 81.77% |
| Sep 30, 2024 | -13.84% |
| Jun 30, 2024 | 28.92% |
| Mar 31, 2024 | 24.65% |
| Dec 31, 2023 | -230.03% |
| Sep 30, 2023 | 72.30% |
| Jun 30, 2023 | 59.15% |
| Mar 31, 2023 | 53.88% |
| Dec 31, 2022 | 101.79% |
| Sep 30, 2022 | 51.20% |
| Jun 30, 2022 | 76.06% |
| Mar 31, 2022 | 88.51% |
| Dec 31, 2021 | -219.81% |
| Sep 30, 2021 | 85.03% |
| Jun 30, 2021 | 84.67% |
| Mar 31, 2021 | -94.38% |